Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.62 |
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KLK7 | P49862 | 2/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943185 | 1.00 | JAK3 (0.62) | JAK3BTKMAPTKLK7KLK5 | |
| SCHEMBL17646424 | 1.00 | JAK3 (0.62) | JAK3BTKMAPTKLK7KLK5 | |
| SCHEMBL16763482 | 0.97 | JAK3 (0.66) | JAK3BTKMAPTKLK7KLK5 | |
| SCHEMBL16763480 | 0.97 | JAK3 (0.66) | JAK3BTKMAPTKLK7KLK5 | |
| SCHEMBL5800857 | 0.96 | JAK3 (0.59) | JAK3BTKMAPTKLK7KLK5 | |
| SCHEMBL19345924 | 0.93 | JAK3 (0.63) | JAK3BTKMAPTKLK7KLK5 | |
| SCHEMBL18942773 | 0.91 | MAPT (0.64) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL2329143 | 0.88 | KLK7 (0.67) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL25540903 | 0.88 | KLK7 (0.67) | MAPTKLK7KLK5ITGB3ITGA2B | |
| SCHEMBL2329138 | 0.88 | KLK7 (0.67) | MAPTKLK7KLK5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332464-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210017167-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3204352-B1 | INHIBITORS OF LYSINE GINGIPAIN | CORTEXYME INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10676470-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190322659-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10301301-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180346460-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-12-06 | — | — | US | disclosed |
| US-9988375-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170349537-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349537-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9758473-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE USA, AS REPRESENTED BY THE SECRETARY, DEPART- MENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2016057413-A2 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096830-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096830-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2015112438-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-05-29 | — | — | US | disclosed |
| US-6291678-B1 | CAN BE INCORPORATED IN INHIBITORS OF SERINE PROTEASES WHICH ARE USED IN THERAPY OF ABNORMAL COAGULATION; THERAPY OR PROPHYLAXIS OF SEPTIC SHOCK, ATHEROSCLEROSIS, ALZHEIMER'S AND PARKINSON'S DISEASE | WARNER-LAMBERT COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0906296-A1 | PROCESS FOR THE PREPARATION OF CHIRAL KETO-HETEROCYCLES OF BASIC AMINO ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048687-A1 | PROCESS FOR THE PREPARATION OF CHIRAL KETO-HETEROCYCLES OF BASIC AMINO ACIDS | WARNER-LAMBERT COMPANY (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346460-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-20190322659-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-20210017167-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-10676470-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-20170002355-A1 | cGAP-PNA MULTIVALENT PEPTIDE NUCLEIC ACID LIGAND DISPLAY | CGAS, STING1, IAPP | JAK3 2118/4885BTK 252/4885MAPT 2874/4885 |
| US-20140148500-A1 | PROGRAMMABLE SELF-ASSEMBLED NANOSTRUCTURES BASED ON SIDECHAIN-MODIFIED PNA FOR THE MULTIVALENT DISPLAY OF LIGANDS | NCL, PARN, COIL | JAK3 2137/4885BTK 315/4885MAPT 3185/4885 |
| US-20170349537-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-20160096830-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-11332464-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
| US-10301301-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | JAK3 2553/4885BTK 1237/4885MAPT 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.